Stockscreener 앱 받기
12.44
2.05%
-0.26
시간 외 거래:
12.43
-0.010
-0.08%
전일 마감가:
$12.70
열려 있는:
$12.68
하루 거래량:
43,424
Relative Volume:
0.48
시가총액:
$316.33M
수익:
$26.00M
순이익/손실:
$-219.71M
주가수익비율:
-0.2498
EPS:
-49.8
순현금흐름:
$-51.37M
1주 성능:
+1.88%
1개월 성능:
+24.40%
6개월 성능:
-37.17%
1년 성능:
-51.41%
1일 변동 폭
$12.43
$13.10
1주일 범위
$11.18
$13.10
52주 변동 폭
$8.85
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
RNAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
12.44 | 316.33M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27% - simplywall.st
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus
Cartesian Therapeutics (RNAC) Issues Inducement Awards to New Em - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Expands Clinical Team: 27,700 Shares Granted to New Biotech Experts - Stock Titan
Cartesian Therapeutics CTO transitions to consultant role By Investing.com - Investing.com India
Cartesian Therapeutics CTO transitions to consultant role - Investing.com
Cartesian Therapeutics CTO Transition to Consultant Role - TipRanks
SEC Form DEF 14A filed by Cartesian Therapeutics Inc. - Quantisnow
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLC - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.67 Consensus Target Price from Brokerages - Defense World
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - ADVFN
Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Shows Efficacy and Safety in Myasthenia Gravis in Phase 2 Study - CGTLive®
JPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
After-Market Momentum Builds For ASP Isotopes (ASPI) Amid Secondary Listing News - Stocks Telegraph
Corebridge Financial Inc. Increases Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at HC Wainwright - Defense World
Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock - Investing.com Australia
Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock By Investing.com - Investing.com South Africa
Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III - The Pharma Letter
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert - Benzinga
Cartesian math works out nicely in phase IIb MG trial - BioWorld MedTech
Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind - insights.citeline.com
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients - Benzinga
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results - TipRanks
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewswire
Breakthrough: New CAR-T Therapy Maintains 83% Response Rate After 12 Months in Myasthenia Gravis Patients - Stock Titan
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World
Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com India
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa
Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada
Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance
Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):